Luca Massacesi

6.8k total citations
123 papers, 3.3k citations indexed

About

Luca Massacesi is a scholar working on Pathology and Forensic Medicine, Immunology and Molecular Biology. According to data from OpenAlex, Luca Massacesi has authored 123 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Pathology and Forensic Medicine, 38 papers in Immunology and 29 papers in Molecular Biology. Recurrent topics in Luca Massacesi's work include Multiple Sclerosis Research Studies (61 papers), Systemic Lupus Erythematosus Research (22 papers) and Polyomavirus and related diseases (19 papers). Luca Massacesi is often cited by papers focused on Multiple Sclerosis Research Studies (61 papers), Systemic Lupus Erythematosus Research (22 papers) and Polyomavirus and related diseases (19 papers). Luca Massacesi collaborates with scholars based in Italy, United States and United Kingdom. Luca Massacesi's co-authors include Clara Ballerini, Bert A. ‘t Hart, Tiziana Biagioli, Alessandro Barilaro, Benedetta Mazzanti, Riccardo Saccardi, Anna Maria Repice, Herbert Brok, Ronald E. Bontrop and Marco Vergelli and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nano Letters.

In The Last Decade

Luca Massacesi

113 papers receiving 3.2k citations

Peers

Luca Massacesi

PFM

IMMUN

NEURO

RHEUM

Andreas Bitsch Germany

Laura Airas Finland

Clas Malmeström Sweden

Wolfgang Br�ck Germany

Imke Metz Germany

Andreas Lutterotti Austria

Elisabetta Capello Italy

Istvan Pirko United States

Rina Aharoni Israel

Markus Axelsson Sweden

Andreas Bitsch Germany

Luca Massacesi

1.8k ×1.1

PFM

727 ×0.8

IMMUN

643 ×0.9

768 ×1.2

NEURO

456 ×0.8

RHEUM

Citations per year, relative to Luca Massacesi Luca Massacesi (= 1×) peers Andreas Bitsch

Countries citing papers authored by Luca Massacesi

Since Specialization

Citations

This map shows the geographic impact of Luca Massacesi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Massacesi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Massacesi more than expected).

Fields of papers citing papers by Luca Massacesi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luca Massacesi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Massacesi. The network helps show where Luca Massacesi may publish in the future.

Co-authorship network of co-authors of Luca Massacesi

This figure shows the co-authorship network connecting the top 25 collaborators of Luca Massacesi. A scholar is included among the top collaborators of Luca Massacesi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luca Massacesi. Luca Massacesi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bertaccini, Bruno, et al.. (2025). A proposal for a machine-learning algorithm for the prediction of seizure recurrence risk at 2 years after discontinuation of anti-seizure medications. Seizure. 133. 73–79.

Pellerin, Alex, Agustín Plasencia, Jordan M. Anderson, et al.. (2025). Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology. Proceedings of the National Academy of Sciences. 122(43). e2505984122–e2505984122.

Mariottini, Alice, et al.. (2024). Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis—The Elephant Is (Still) in the Room. Microorganisms. 12(10). 1941–1941.

Mariottini, Alice, Fabrizia Mealli, Alessandra Mattei, & Luca Massacesi. (2024). Comparative efficacy of subcutaneous versus intravenous natalizumab on annualized relapse rate: A post-hoc analysis of the REFINE study. Multiple Sclerosis and Related Disorders. 91. 105852–105852. 2 indexed citations

Giovannelli, G, et al.. (2023). Alice in wonderland syndrome “through the looking-glass” in a rare presentation of non-convulsive status epilepticus in cerebral venous sinus thrombosis and COVID-19. Cortex. 167. 218–222. 1 indexed citations

Mariottini, Alice, Anna Maria Repice, Chiara Nozzoli, et al.. (2023). Effect of the COVID‐19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation. European Journal of Neurology. 30(10). 3362–3366.

Barilaro, Alessandro, et al.. (2023). Case report: 3D intracranial vessel wall MRI in Susac syndrome: potential relevance for diagnosis and therapeutic management. Frontiers in Neurology. 14. 1201643–1201643. 1 indexed citations

Mariottini, Alice, Anna Maria Repice, Alessandro Barilaro, et al.. (2022). Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents. Multiple Sclerosis and Related Disorders. 60. 103679–103679. 5 indexed citations

Farina, Antonio, Matteo Gastaldi, Alessandro Barilaro, et al.. (2022). Leptomeningeal Gadolinium Enhancement in Autoimmune GFAP Astrocytopathy. Neurology. 98(17). 720–722. 3 indexed citations

10.

Bertaccini, Bruno, et al.. (2021). Prediction of seizure recurrence risk following discontinuation of antiepileptic drugs. Epilepsia. 62(9). 2159–2170. 29 indexed citations

11.

Mariottini, Alice, et al.. (2020). Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 47. 102591–102591. 10 indexed citations

12.

Signori, Alessio, Giacomo Boffa, Francesca Bovis, et al.. (2020). Prevalence of disability improvement as a potential outcome for multiple sclerosis trials. Multiple Sclerosis Journal. 27(5). 706–711. 7 indexed citations

13.

Steingo, Brian, Yaser Al Malik, Ann Bass, et al.. (2020). Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. Journal of Neurology. 267(11). 3343–3353. 41 indexed citations

14.

Maggi, Pietro, Martina Absinta, Pascal Sati, et al.. (2019). The “central vein sign” in patients with diagnostic “red flags” for multiple sclerosis: A prospective multicenter 3T study. Multiple Sclerosis Journal. 26(4). 421–432. 54 indexed citations

15.

Maggi, Pietro, Martina Absinta, Luisa Vuolo, et al.. (2018). Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Annals of Neurology. 83(2). 283–294. 153 indexed citations

16.

Tesio, Luigi, et al.. (2018). Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis: A Randomized Clinical Trial. Journal of Vascular Surgery Venous and Lymphatic Disorders. 6(3). 419–419. 8 indexed citations

17.

Hart, Bert A. ‘t, Marjan van Meurs, Herbert Brok, et al.. (2000). A new primate model for multiple sclerosis in the common marmoset. Immunology Today. 21(6). 290–297. 92 indexed citations

18.

Ballerini, Clara, et al.. (1999). HLA A2 allele is associated with age at onset of Alzheimer's disease. Annals of Neurology. 45(3). 397–400. 28 indexed citations

19.

D’Alfonso, Sandra, Lorenza Nisticò, Patrizia Zavattari, et al.. (1999). Linkage analysis of multiple sclerosis with candidate region markers in Sardinian and Continental Italian families. European Journal of Human Genetics. 7(3). 377–385. 38 indexed citations

20.

Matà, Sabrina, Marco Vergelli, Elena Nardi, et al.. (1999). A synthetic glycopeptide of human myelin oligodendrocyte glycoprotein to detect antibody responses in multiple sclerosis and other neurological diseases. Bioorganic & Medicinal Chemistry Letters. 9(2). 167–172. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact